Start-Ups Swimming ...
Health Care: Drugs
Apricus Biosciences Inc. (APRI: NASDAQ)
$2.58 -0.07 | -2.64%
05/24/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 15.13M | 7.43M | 9.15M | 479.89K |
| Receivables | 678.00K | 326.93K | 538.78K | 1.15M |
| Inventories | 0.00 | 136.15K | 0.00 | 0.00 |
| Other Current Assets | 4.44M | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 20.90M | 8.19M | 10.48M | 1.77M |
| Property, Plant & Equipment, Gross | 698.00K | 7.94M | 10.87M | 10.45M |
| Accumulated Depreciation & Depletion | 97.00K | 3.55M | 5.45M | 4.83M |
| Property, Plant & Equipment, Net | 601.00K | 4.38M | 5.42M | 5.62M |
| Intangibles | 0.00 | 2.63M | 2.70M | 4.15M |
| Other Non-Current Assets | 2.38M | 280.19K | 263.88K | 319.94K |
| Total Non-Current Assets | 2.98M | 8.42M | 8.39M | 19.17M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 23.88M | 16.62M | 18.86M | 20.93M |
| Accounts Payable | 2.28M | 1.14M | 789.54K | 1.55M |
| Short Term Debt | 0.00 | 4.27K | 432.26K | 24.53K |
| Other Current Liabilities | 3.94M | 1.68M | 68.60K | 70.00K |
| Total Current Liabilities | 10.77M | 10.02M | 2.32M | 14.17M |
| Long Term Debt | 3.41M | 0.00 | 4.00M | 2.99M |
| Deferred Income Taxes | 1.53M | 0.00 | 805.79K | 865.60K |
| Other Non-Current Liabilities | 1.55M | 1.76M | 72.25K | 82.45K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 6.49M | 1.78M | 4.98M | 4.05M |
| Total Liabilities | 17.26M | 11.80M | 7.30M | 18.23M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 6.62M | 4.82M | 11.57M | 2.71M |
| Common Par | 30.00K | 21.35K | 18.52K | 104.82K |
| Additional Paid In Capital | 257.08M | 224.15M | 212.79M | 174.33M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -251.13M | -219.36M | -201.24M | -171.73M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 641.00K | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 10.03M | 4.82M | 15.57M | 5.70M |
| Total Equity | 6.62M | 4.82M | 11.57M | 2.71M |
| Total Liabilities & Stock Equity | 23.88M | 16.62M | 18.86M | 20.93M |
| Total Common Shares Outstanding | 29.94M | 21.35M | 18.52M | 6.99M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 27.46M | 20.02M | 11.85M | 5.91M |
| Diluted Weighted Shares Outstanding | 27.46M | 20.02M | 11.85M | 5.91M |
| Number of Employees | 114 | 25 | 35 | 34 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with APRI
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
Latest APRI Headlines from TheStreet
- Apricus Biosciences To Present At 2013 BIO International Convention 04.18.13 | 07:04 am
- Apricus Biosciences Announces Sale Of Non-Core Assets 04.01.13 | 04:04 pm
- Apricus Biosciences Provides Corporate Update; Files Annual Report For Quarter And Year Ended December 31, 2012 03.18.13 | 11:03 am
- Apricus Biosciences Appoints Richard W. Pascoe As Chief Executive Officer 03.18.13 | 11:03 am
- Apricus Biosciences Announces 2012 Year End Financial Results Conference Call 03.14.13 | 09:03 am
- Apricus Biosciences Announces Ceasing Of Financing Of French Subsidiaries 03.14.13 | 08:03 am
- Apricus Biosciences To Present At The 25th Annual ROTH Conference 03.13.13 | 04:03 pm
- Apricus Biosciences To Present At BIO-Europe Spring 2013 03.07.13 | 08:03 am
- Apricus Biosciences To Present At The 15th Annual BIO CEO & Investor Conference 02.06.13 | 08:02 am
- 5 Stocks Poised for Breakouts 02.01.13 | 01:02 pm
Press Releases for APRI
- Apricus Biosciences, Inc. (APRI) Transforms From Development Company To Income Generating! - PR Newswire 03.14.12 | 09:03 am
- Apricus Biosciences To File For Market Authorization To Sell Vitaros® For Erectile Dysfunction In Latin America - PR Newswire 08.08.11 | 07:08 pm
- Apricus Biosciences Launches Educational Video Series Focused On Its Newly Approved Erectile Dysfunction Drug, Vitaros® - Business Wire 12.06.10 | 09:12 am
- Apricus Biosciences Appoints Manufacturer For Vitaros®, Its Newly Approved Drug To Treat Erectile Dysfunction In Canada - Business Wire 12.01.10 | 10:12 am
- Apricus Biosciences Announces New NexACT® Transbuccal Delivery Data Published In The International Journal Of Pharmaceutics - Business Wire 11.29.10 | 10:11 am
- Apricus Biosciences Files Phase 3 Registration Protocol For PrevOnco™ For Special Protocol Assessment Consideration By The FDA - Business Wire 11.22.10 | 10:11 am
- Apricus Bio Announces Pre-Clinical Data Showing Significant Improvement In Solubility And Absorption Of NexACT®-Based Small Molecule Drugs Selected From The Biopharmaceutics Classification System - Business Wire 11.19.10 | 10:11 am
- Apricus Biosciences’ CEO Bassam Damaj, Ph.D., Interviewed By The Financial Network CDTV.net - Business Wire 11.17.10 | 10:11 am
- Apricus Biosciences Receives Canadian Approval For Vitaros® As First Line Therapy For Erectile Dysfunction - Business Wire 11.15.10 | 12:11 pm
- Apricus Biosciences Announces 2010 Third Quarter Financial Results Conference Call - Business Wire 11.10.10 | 10:11 am
Partner Headlines for APRI
- 7 top stocks under $5 - MSN Money 05.16.13 | 03:05 pm
- Smart Stocks Watch: Apricus Biosciences - Seeking Alpha 09.21.12 | 09:09 am
- Apricus, Takeda Ink Marketing Deal - Analyst Blog - NASDAQ 09.14.12 | 10:09 pm
- Apricus, Takeda Ink Marketing Deal - Analyst Blog - Zacks 09.14.12 | 06:09 pm
- Tesaro Initiated at OUTPERFORM and 2 Initiated Shares on the Move - Wall St. Cheat Sheet 07.23.12 | 04:07 am
- REVEALED: New Stock Analyst Coverage to Evaluate - Wall St. Cheat Sheet 06.14.12 | 03:06 am
- Apricus Biosciences Strengthens Vitaros and Nexact Patent Estate With Two New Patent Allowances - Benzinga 05.25.12 | 01:05 pm
- Apricus Biosciences Granted Regulatory Meeting With FDA for Femprox(R) for the Treatment of Female Sexual Arousal Disorder - Benzinga 05.21.12 | 09:05 am
- Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa(TM) for the Treatment of Onychomycosis - Benzinga 05.11.12 | 09:05 am
- Apricus Biosciences; Vitaros Has Great Potential - Seeking Alpha 04.22.12 | 09:04 am
